Skip to main content
SpringerLink
Log in

Indications for Hematopoietic Transplantation for AML

  • Chapter
  • First Online:
Targeted Therapy of Acute Myeloid Leukemia

Part of the book series: Current Cancer Research ((CUCR))

  • 1983 Accesses

Abstract

Allogeneic hematopoietic cell transplantation (AHCT) is an effective treatment for AML. This approach has been extensively evaluated in patients with AML and is indicated for patients in first remission with intermediate- to high-risk features, those with primary refractory disease or early relapse. Patients have traditionally received transplants from a human leukocyte antigen (HLA)-matched sibling donor. Improvements in HLA typing allowing identification of complete allele level matches have improved the results of unrelated donor transplants and results are now comparable with matched siblings. Recently, there have been major advances using HLA-nonidentical donors including haploidentical, one antigen mismatched unrelated donors or cord blood units, and an acceptable donor can now be identified for nearly all patients in need of a hematopoietic transplant.

In this chapter, we will review the indications for transplantation in acute myelogenous leukemia:

  • First complete remission; consideration for risk categories for relapse:

    • Favorable risk acute myeloid leukemia (AML)

    • Intermediate-risk AML

    • Unfavorable-risk AML

    • Therapy-related AML

  • Transplant in relapsed or refractory settings

  • Autologous versus allogeneic transplantation

  • Allogeneic donor categories

  • Relapse post transplant, consideration for second allogeneic transplant

  • Reduced intensity conditioning

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alatrash G, de Lima M, Hamerschlak N et al (2011) Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 17:1490–1496

    PubMed Central  CAS  PubMed  Google Scholar 

  • Anasetti C, Aversa F, Brunstein CG (2012) Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? Biol Blood Marrow Transplant 18:161–165

    Google Scholar 

  • Anasetti C, Logan B, Lee SJ et al (2011) increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: results of blood and marrow transplant clinical trials network (BMT CTN) protocol 0201, a phase iii, prospective, randomized trial. Blood 118:3

    Google Scholar 

  • Armand P, Kim HT, Cutler CS et al (2008) A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14:28–35

    PubMed Central  CAS  PubMed  Google Scholar 

  • Armistead PM, de Lima M, Pierce S et al (2009) Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15:1431–1438

    PubMed Central  PubMed  Google Scholar 

  • Barker JN, Weisdorf DJ, DeFor TE et al (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:1343–1347

    CAS  PubMed  Google Scholar 

  • Barker JN, Byam CE, Kernan NA et al (2010) Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 16:1541–1548

    PubMed Central  PubMed  Google Scholar 

  • Bayraktar UD, Champlin RE, Ciurea SO (2012) Progress in haploidentical stem cell transplantation. Biol Blood Marrow Transplant 18:372–380

    PubMed  Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458

    CAS  PubMed  Google Scholar 

  • Bensinger WI, Weaver CH, Appelbaum FR et al (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655–1658

    CAS  PubMed  Google Scholar 

  • Bensinger WI, Martin PJ, Storer B et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175–181

    CAS  PubMed  Google Scholar 

  • Bloomfield CD, Lawrence D, Byrd JC et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179

    CAS  PubMed  Google Scholar 

  • Borthakur G, Estey AE (2007) Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 9:373–377

    CAS  PubMed  Google Scholar 

  • Broxmeyer HE, Hangoc G, Cooper S et al (1992) Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A 89:4109–4113

    PubMed Central  CAS  PubMed  Google Scholar 

  • Brunet S, Labopin M, Esteve J et al (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30:735–741

    PubMed  Google Scholar 

  • Brunstein CG, Laughlin MJ (2010) Extending cord blood transplant to adults: dealing with problems and results overall. Semin Hematol 47:86–96.

    PubMed  Google Scholar 

  • Brunstein CG, Gutman JA, Weisdorf DJ et al (2010) Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693–4699

    PubMed Central  CAS  PubMed  Google Scholar 

  • Buccisano F, Maurillo L, Spagnoli A et al (2010) Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 116:2295–2303

    CAS  PubMed  Google Scholar 

  • Buccisano F, Maurillo L, Del Principe MI et al (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119:332–341

    CAS  PubMed  Google Scholar 

  • Byrd JC, Mrozek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336

    CAS  PubMed  Google Scholar 

  • Caligiuri MA, Strout MP, Lawrence D et al (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55–59

    CAS  PubMed  Google Scholar 

  • Candoni A, Toffoletti E, Gallina R et al (2011) Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 25:308–316

    CAS  PubMed  Google Scholar 

  • Carlens S, Remberger M, Aschan J, Ringden O (2001) The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 7:31–38

    CAS  PubMed  Google Scholar 

  • Champlin R (2011) Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. Biol Blood Marrow Transplant 17:1723–1724

    PubMed Central  PubMed  Google Scholar 

  • Champlin R, Khouri I, Shimoni A et al (2000a) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18–29

    CAS  PubMed  Google Scholar 

  • Champlin RE, Schmitz N, Horowitz MM et al (2000b) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95:3702–3709

    CAS  PubMed  Google Scholar 

  • Ciceri F, Labopin M, Aversa F et al (2008) A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112:3574–3581

    CAS  PubMed  Google Scholar 

  • Clift RA, Buckner CD, Appelbaum FR et al (1992) Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10:1723–1729

    CAS  PubMed  Google Scholar 

  • Cornelissen JJ, van Putten WL, Verdonck LF et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109:3658–3666

    CAS  PubMed  Google Scholar 

  • de Botton S, Fawaz, Chevret S et al (2005) Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 23:120–126

    PubMed  Google Scholar 

  • Delhommeau F, Dupont S, Della Valle V et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289–2301

    PubMed  Google Scholar 

  • De Zern AE, Sung A, Kim S et al (2011) Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 17:1404–1409

    Google Scholar 

  • Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474

    PubMed  Google Scholar 

  • Duval M, Klein JP, He W et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28:3730–3738

    PubMed Central  PubMed  Google Scholar 

  • Dvorak CC, Agarwal R, Dahl GV, Gregory JJ, Feusner JH (2008) Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant 14:824–830

    PubMed Central  PubMed  Google Scholar 

  • Eapen M, Giralt SA, Horowitz MM et al (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transpl 34:721–727

    CAS  Google Scholar 

  • Eapen M, Rocha V, Sanz G et al (2010) Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 11:653–660

    PubMed Central  PubMed  Google Scholar 

  • Falini B, Martelli MP, Bolli N et al (2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117:1109–1120

    CAS  PubMed  Google Scholar 

  • Farag SS, Maharry K, Zhang MJ et al (2011) Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60–70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 17:1796–1803

    PubMed  Google Scholar 

  • Frederick RA, Stephen JF, Robert SN, Karl GB (eds) (2011) Thomas’ hematopoietic cell transplantation, 4th edn. Wiley-Blackwell, Malden, pp 761–774

    Google Scholar 

  • Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532–1542

    CAS  PubMed  Google Scholar 

  • Gluckman E, Rocha V, Boyer-Chammard A et al (1997) Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337:373–381

    CAS  PubMed  Google Scholar 

  • Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091–2101

    PubMed Central  CAS  PubMed  Google Scholar 

  • Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE (2010) Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 28:2739–2747

    CAS  PubMed  Google Scholar 

  • Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354–365

    CAS  PubMed  Google Scholar 

  • Gupta V, Tallman MS, He W et al (2010) Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 116:1839–1848

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gyurkocza B, Storb R, Storer BE et al (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28:2859–2867

    PubMed Central  PubMed  Google Scholar 

  • Horan JT, Logan BR, Agovi-Johnson MA et al (2011) Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 29:805–813

    PubMed Central  PubMed  Google Scholar 

  • Horowitz MM, Gale RP, Sondel PM et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562

    CAS  PubMed  Google Scholar 

  • Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (2011) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission. posted to the SEER web site, 2011

  • Hubel K, Weingart O, Naumann F et al (2011) Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leuk Lymphoma 52:444–457

    PubMed  Google Scholar 

  • Jourdan E, Boiron JM, Dastugue N et al (2005) Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 23:7676–7684

    PubMed  Google Scholar 

  • Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078–3085

    CAS  PubMed  Google Scholar 

  • Korbling M, Przepiorka D, Huh YO et al (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659–1665

    CAS  PubMed  Google Scholar 

  • Koreth J, Schlenk R, Kopecky KJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349–2361

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kroger N, Brand R, van Biezen AF et al (2009) Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 94:542–549

    PubMed Central  PubMed  Google Scholar 

  • Kronke J, Schlenk RF, Jensen KO et al (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 29:2709–2716

    PubMed  Google Scholar 

  • Kurtzberg J, Prasad VK, Carter SL et al (2008) Results of the cord blood transplantation study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112:4318–4327

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lee SJ, Klein J, Haagenson M et al (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110:4576–4583

    CAS  PubMed  Google Scholar 

  • Linker CA, Owzar K, Powell B et al (2009) Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 44:353–359

    CAS  PubMed  Google Scholar 

  • Litzow MR, Tarima S, Perez WS et al (2010) Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115:1850–1857

    PubMed Central  CAS  PubMed  Google Scholar 

  • Marcucci G, Maharry K, Radmacher MD et al (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26:5078–5087

    PubMed Central  CAS  PubMed  Google Scholar 

  • Marcucci G, Maharry K, Wu YZ et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28:2348–2355

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mardis ER, Ding L, Dooling DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058–1066

    PubMed Central  CAS  PubMed  Google Scholar 

  • Martino R, Iacobelli S., Brand R et al (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836–846

    CAS  PubMed  Google Scholar 

  • McSweeney PA, Niederwieser D, Shizuru JA et al (1999) Outpatient allografting with minimally myeosuppressive immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and mycophenolate mofetil. Blood 94(1):393a

    Google Scholar 

  • Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR (2010) Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 116:2224–2228

    PubMed Central  CAS  PubMed  Google Scholar 

  • Metzeler KH, Becker H, Maharry K et al (2011a) ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118:6920–6929

    PubMed Central  CAS  PubMed  Google Scholar 

  • Metzeler KH, Maharry K, Radmacher MD et al (2011b) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 29:1373–1381

    PubMed Central  PubMed  Google Scholar 

  • Mielcarek M, Storer B, Martin PJ et al (2012) Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 119:2675–2678

    Google Scholar 

  • Moreno I, Martin G, Bolufer P et al (2003) Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 88:19–24

    CAS  PubMed  Google Scholar 

  • Mrozek K (2008) Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 35:365–377

    PubMed Central  CAS  PubMed  Google Scholar 

  • Paschka P, Marcucci G, Ruppert AS et al (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904–3911

    CAS  PubMed  Google Scholar 

  • Patel JP, Gonen M, Figueroa ME et al (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366:1079–1089

    PubMed Central  CAS  PubMed  Google Scholar 

  • Paun O, Lazarus HM (2012) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission: have the indications changed? Curr Opin Hematol 19:95–101

    PubMed  Google Scholar 

  • Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B (2009) Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1415–1421

    PubMed  Google Scholar 

  • Ringden O, Labopin M, Bacigalupo A et al (2002) Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 20:4655–4664

    CAS  PubMed  Google Scholar 

  • Ringden O, Labopin M, Ehninger G et al (2009) Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 27:4570–4577

    PubMed  Google Scholar 

  • Rubinstein P, Carrier C, Scaradavou A et al (1998) Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339:1565–1577

    CAS  PubMed  Google Scholar 

  • Ruggeri L, Mancusi A, Capanni M et al (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110:433–440

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ruggeri A, Ciceri F, Gluckman E, Labopin M, Rocha V (2010) Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: umbilical cord blood or haploidentical donors? Best Pract Res Clin Haematol 23:207–216

    PubMed  Google Scholar 

  • Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J (2012) Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 119:3908–3916

    PubMed Central  CAS  PubMed  Google Scholar 

  • Schlenk RF, Dohner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918

    CAS  PubMed  Google Scholar 

  • Schlenk RF, Dohner K, Mack S et al (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642–4648

    Google Scholar 

  • Schmid C, Labopin M, Nagler A et al (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119:1599–1606

    CAS  PubMed  Google Scholar 

  • Schmitz N, Bacigalupo A, Hasenclever D et al (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995–1003

    CAS  PubMed  Google Scholar 

  • Schmitz N, Dreger P, Suttorp M et al (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666–1672

    CAS  PubMed  Google Scholar 

  • Schmitz N, Beksac M, Hasenclever D et al (2002) Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 100:761–767

    CAS  PubMed  Google Scholar 

  • Schmitz N, Eapen M, Horowitz MM et al (2006) Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108:4288–4290

    PubMed Central  CAS  PubMed  Google Scholar 

  • Shimoni A, Kroger N, Zabelina T et al (2005) Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 19:7–12

    CAS  PubMed  Google Scholar 

  • Slavin S, Nagler A, Naparstek E et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763

    CAS  PubMed  Google Scholar 

  • Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075–4083

    CAS  PubMed  Google Scholar 

  • Soiffer RJ, Lerademacher J, Ho V et al (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117:6963–6970

    PubMed Central  CAS  PubMed  Google Scholar 

  • Suciu S, Mandelli F, de Witte T et al (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102:1232–1240

    CAS  PubMed  Google Scholar 

  • Symons H, Chen AR, Leffell MS et al (2010) HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative. Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Blood 116:977

    Google Scholar 

  • Szydlo R, Goldman JM, Klein JP et al (1997) Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15:1767–1777

    CAS  PubMed  Google Scholar 

  • Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114:5126–5135

    CAS  PubMed  Google Scholar 

  • Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011–4020

    CAS  PubMed  Google Scholar 

  • Truitt RL, Johnson BD (1995) Principles of graft-vs.-leukemia reactivity. Biol Blood Marrow Transplant 1:61–68

    CAS  PubMed  Google Scholar 

  • Van Vlierberghe P, Patel J, Abdel-Wahab O et al (2011) PHF6 mutations in adult acute myeloid leukemia. Leukemia 25:130–134

    PubMed  Google Scholar 

  • Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951

    CAS  PubMed  Google Scholar 

  • Wang J, Ouyang J, Zhou R, Chen B, Yang Y (2010) Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol 124:61–71

    PubMed  Google Scholar 

  • Ward PS, Patel J, Wise DR et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234

    PubMed Central  CAS  PubMed  Google Scholar 

  • Whitman SP, Caligiuri MA, Maharry K et al (2012) The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia 26:1713–1717

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yamamoto Y, Kiyoi H, Nakano Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439

    CAS  PubMed  Google Scholar 

  • Yan XJ, Xu J, Gu ZH et al (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43:309–315

    CAS  PubMed  Google Scholar 

  • Yanada M, Matsuo K, Emi N, Naoe T (2005) Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103:1652–1658

    PubMed  Google Scholar 

  • Zittoun RA, Mandelli F, Willemze R et al (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217–223

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 423, 77030, Houston, TX, USA

    Sairah Ahmed M.D. & Richard Champlin M.D.

Authors
  1. Sairah Ahmed M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Champlin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Champlin M.D. .

Editor information

Editors and Affiliations

  1. Dept. Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Michael Andreeff

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag New York

About this chapter

Cite this chapter

Ahmed, S., Champlin, R. (2015). Indications for Hematopoietic Transplantation for AML. In: Andreeff, M. (eds) Targeted Therapy of Acute Myeloid Leukemia. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1393-0_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1393-0_42

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1392-3

  • Online ISBN: 978-1-4939-1393-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation